#Denmark #Copenhagen #diabetes #Glooko #Hedia

Glooko and Hedia Join Forces to Transform Diabetes Care

Glooko, Inc. and Hedia recently unveiled a groundbreaking interoperable solution designed to enhance the management of diabetes for patients who require advanced insulin dosage assistance. This initiative merges connected care services, remote patient monitoring, and digital therapeutic technologies to streamline diabetes management for those living with Type 1 and Type 2 diabetes. Initially targeting the UK market, this innovative system is set to expand into various European countries over time.

Understanding the Challenge of Insulin Dosage

Insulin bolus dosing is critical for patients, especially around meal times or when experiencing blood sugar spikes. Typically, it requires one unit of insulin to reduce glucose levels by approximately 50 mg/dl. However, this calculation can be complex and often challenging for individuals without access to insulin pumps.

Through the Glooko platform, patients can effortlessly share vital diabetes-related data with healthcare providers. This includes glucose readings, insulin doses, dietary intake, carbohydrate counts, physical activity logs, blood pressure measurements, and weight records. The seamless integration of the Hedia Diabetes Assistant into Glooko's platform allows for customized assistance in calculating insulin doses, ultimately leading to better diabetes management and consistent blood sugar levels.

Benefits for Healthcare Providers

This new approach not only enhances patient outcomes but also provides healthcare providers with enhanced visibility into their patients’ health metrics. Providers benefit from easy access to comprehensive patient data, which includes glucose logs, insulin doses, carbohydrate intake, and activity levels, among other parameters. This streamlined management of daily injections can significantly improve both patient outcomes and healthcare efficiency, whether delivery is remote or in-person.

Mike Alvarez, CEO of Glooko, expressed enthusiasm about this new partnership, stating, "We are thrilled to bring this algorithm-based personalized innovation to diabetic patients and their healthcare teams through our collaboration with Hedia. This solution serves as a crucial alternative for individuals who cannot access insulin pumps, ensuring more effective therapy management."

Commitment to Quality and Compliance

Lars Christian Lund, CEO of Hedia, shared his excitement about the partnership, underscoring Glooko's extensive clinical network. Lund emphasized that this collaboration aligns seamlessly with Hedia's mission to enhance the quality of life for diabetic patients and provide superior management tools. Hedia has recently obtained MDR certification in Europe, validating their commitment to regulatory compliance to ensure patients receive the highest quality solutions.

About Hedia and Glooko

Hedia specializes in digital therapies for diabetes and is dedicated to helping insulin-dependent patients manage their condition effectively. Their app leverages individual habits and personalized data to offer insulin recommendations, tracking ways to improve diabetes management. Meanwhile, Glooko aims to transform the health of individuals with chronic conditions through a connected and intelligent platform, facilitating better health outcomes across over 30 countries and 10,000 clinical sites.

In summary, the partnership between Glooko and Hedia represents a significant leap forward in diabetes management technology. By providing personalized insulin dosage options, they are paving the way for improved treatment outcomes and a better quality of life for those affected by diabetes.